EquiCeutica announces Dr Rodrigo Zamith Cunha VM DVM MSc – Chief Scientific and Veterinary Officer

“I am thrilled to start this collaboration and excited about the potential we have to significantly enhance the well-being of our patients and achieve better clinical outcomes. I am enthusiastic to take a hands-on approach to drive these advancements forward.”                                                                                                                  Zamith, Rodrigo. January 2025

EquiCeutica takes great pleasure in announcing the appointment, with effect from the 1st January 2025, of Dr Rodrigo Zamith Cunha VM DVM MSc as Chief Scientific and Veterinary Officer of EquiCeutica Limited.

Dr Rodrigo Zamith Cunha is recognized internationally for his pioneering work in advancing the scientific understanding of the Endocannabinoid System in veterinary clinical therapy to enhance the welfare of animals through the development of innovative therapeutic solutions.

Rodrigo will direct EquiCeutica’s program of clinical trials with EquiCeutica Liposomal CBD, following consistent positive treatment outcomes observed by pre-eminent veterinary clinicians prescribing EquiCeutica CBD to equine and small animal patients.

Rodrigo has double degrees in Veterinary Medicine, from the Universidade Federal Rural do Rio de Janeiro and the University of Bologna. He is currently a Researcher  at the University of Bologna, engaged in research collaboration involving the localisation of cannabinoids and cannabinoids related receptors in veterinary patients and its use as a curative target for therapy. He is also a Clinical Researcher at the University of Teramo, where he is conducting molecular research on the mapping of the Endocannabinoid System of small animals.

Rodrigo was an Intern with Bosdreef Equine Hospital and an Extern with Donnington Grove Equine Hospital, Liphook Equine Hospital, The Royal Veterinary College and Bosdreef Equine Hospital. 

Rodrigo’s work has resulted in more than eight scientific publications, listed on our home page. 

EquiCeutica Liposomal CBD is now prescribed by more than 30 of the leading Equine Hospitals/Clinics and Veterinary practices in the UK and the EU. EquiCeutica CBD is used by vets in surgery as part of multi-modal analgesia and also more generally as part of a multi-modal approach to treating various conditions. It is also used in “end of life” procedures. It is observed to enhance efficacy when used in conjunction with NSAID’s.  Vets have observed “successful treatment of emaciated horses that would not eat, anxious horses in the hospital and a stallion”.

Prominent competition vets in most international disciplines have observed significantly enhanced recovery times for horses prescribed with EquiCeutica CBD.

Veterinary controlled Field Case Studies have been mostly conducted with equine but consistent positive patient treatment outcomes have been observed with small animals, canine and feline, particularly with older emaciated and immobile dogs.

“The application of SAIFX liposomal encapsulation technology to EquiCeutica’s certified pharmaceutical grade CBD, is pioneering the use of liposomal delivery systems in the world of human and veterinary medicines and will definitely provide unparalleled benefits to the normal dosage forms. We are looking forward to developing further clinical trials and other crucial innovations.” 

Professor Mohammad Najlah. Chief Scientist, GM Priority Pharma Limited, Professor of Pharmceutics and Nano-Medicines, Anglia Ruskin University. 

EquiCeutica is pioneering pharmaceutical grade cannabidiol (CBD) research and development for humans and animals. We are one of the only companies focussing on regulatory approved CBD products for horses and small animals.